40th week of 2021 patent applcation highlights part 10 |
Patent application number | Title | Published |
20210308132 | FGFR INHIBITOR FOR USE IN THE TREATMENT OF HYPOPHOSPHATEMIC DISORDERS - The present invention relates generally to 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof or a pharmaceutical composition comprising 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimid-4-yl}-1-methyl-urea or a pharmaceutically acceptable salt or solvate thereof for use in the treatment of X-linked hypophosphatemic rickets (XLH), autosomal dominant hypophosphatemic rickets (ADHR), autosomal recessive hypophosphatemic rickets (ARHR), tumor-induced osteomalacia, post-renal transplant hypophosphatemia, epidermal nevus syndrome, osteoglophonic dysplasia or McCune-Albright syndrome. | 2021-10-07 |
20210308133 | METHODS AND COMPOSITIONS FOR INHIBITING MUSCLE WASTING - Method of reducing or preventing muscle loss, such as from cancer-induced cachexia, p38β MAPK inhibitors are provided. Compositions for use in such methods are also provided. | 2021-10-07 |
20210308134 | TREATMENT OF EGFR-MUTANT CANCER - Disclosed herein are methods for treating an EGFR-mutant cancer in a patient in need thereof by administering to the patient a therapeutically effective amount of at least one RET inhibitor (e.g., Compound 1 and/or pharmaceutically acceptable salts thereof) and a therapeutically effective amount of at least one EGFR inhibitor (e.g., osimertinib and/or pharmaceutically acceptable salts thereof), as well as combination therapies including at least one RET inhibitor and at least one EGFR inhibitor. | 2021-10-07 |
20210308135 | Dosing Regimens for Elagolix - The present invention relates to dosing regimens for GnRH receptor antagonists, and, in particular, dosing regimens for 4-((R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-(2-fluoro-6-trifluoromethyl-benzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidin-1-yl]-1- phenylethylamino)-butyric acid (Compound A) or a pharmaceutically acceptable salt thereof, in subjects suffering from, for example, endometriosis, adenomyosis, polycystic ovary syndrome (PCOS), or uterine fibroids, to minimize changes in bone mineral density associated with such GnRH receptor antagonists. | 2021-10-07 |
20210308136 | COMBINATION THERAPY COMPRISING AN ACC INHIBITOR - The present disclosure provides methods and compositions for treating, stabilizing or lessening the severity or progression of a non-alcoholic fatty liver disease. | 2021-10-07 |
20210308137 | ANTIVIRAL COMPOUNDS AND METHOD FOR TREATING HEPATOTROPIC VIRAL INFECTION, PARTICULARLY HEPATITIS B AND HEPATITIS D - The present invention provides a compound or a method for treating a hepatotropic viral infection in a human, particularly hepatitis B and hepatitis D, wherein the compound is a certain tricyclic compound. | 2021-10-07 |
20210308138 | TISSUE TRANSGLUTAMINASE MODULATORS FOR MEDICINAL USE - The present invention relates to a compound which is a modulator of tissue transglutaminase (TG2) for use in the treatment of endothelial dysfunction and diseases related thereto or resulting therefrom. In particular the present invention relates to the compound LDN-27219 (Formula II herein) and derivatives thereof for use in the treatment of diseases resulting from endothelial dysfunction, especially in association with aging and diabetic subjects. | 2021-10-07 |
20210308139 | FOLATE PREPARATIONS - Preparations of folate for use in the treatment of eye disorders in the presence of elevated intraocular pressure. Methods of reducing intraocular pressure in a patient having an eye disease. | 2021-10-07 |
20210308140 | NLRP3 INFLAMMASOME INHIBITORS - The present invention relates to novel thienopyrrolotriazinacetamide compounds of Formula (I): wherein R | 2021-10-07 |
20210308141 | POLYSUBSTITUTED BENZENE COMPOUND AND PREPARATION METHOD AND USE THEREOF - The present invention provides a novel EZH2 inhibitor compound represented by formula (I) and a use of the inhibitor compound in preventing or treating a disease mediated by EZH2. | 2021-10-07 |
20210308142 | MODIFIED RELEASE PREPARATIONS CONTAINING OXCARBAZEPINE AND DERIVATIVES THEREOF - Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed. | 2021-10-07 |
20210308143 | COMPOSITIONS AND METHODS FOR REDUCING BODY FAT - The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions. | 2021-10-07 |
20210308144 | Synthesis of New Potent Aromatase Inhibitors Through Biocatalysis of Anti-Cancer Drugs, Atamestane, Drostanolone Enanthate, and Exemestane - New analogues of anti-cancer drugs atamestane ( | 2021-10-07 |
20210308145 | Pharmaceutical Composition - A pharmaceutical composition comprising. (A) androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. | 2021-10-07 |
20210308146 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 2021-10-07 |
20210308147 | USE OF ANDROGENS FOR TREATING CORONA VIRUS - By initially lowering the SHBG with a synthetic androgen and, thereafter, raising the testosterone level in a person's body, an effective method for treating a corona virus is achieved by first using a synthetic anabolic steroid and, thereafter, a natural androgen. | 2021-10-07 |
20210308148 | PHARMACEUTICAL USE - The invention relates to the use of a pharmaceutical medication comprising an aromatase inhibitor, preferably a steroidal aromatase inactivator and an antioxidant as effective ingredients for the treatment of sex hormone-dependent diseases. Furthermore, the invention relates to a composition comprising an aromatase inhibitor/—inactivator and a-lipoic acid and/or extract of green tea containing polyphenols. The combination of an aromatase inhibitor and—inactivator and a-lipoic acid and/or extract of green tea containing polyphenols is particularly suitable for the treatment of sex hormone-dependent diseases as well as for the treatment of benign tumors such as e.g. lipomatoses as occurring in Madelung's disease. | 2021-10-07 |
20210308149 | NEUROACTIVE 19-ALKOXY-17-SUBSTITUTED STEROIDS, PRODRUGS THEREOF, AND METHODS OF TREATMENT USING SAME - The present disclosure is generally directed to neuroactive 19-alkoxy-17-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the treatment of disorders relating to GABA function and activity. The present disclosure is further directed to pharmaceutical compositions comprising such compounds. | 2021-10-07 |
20210308150 | Pharmaceutical Compositions - A pharmaceutical composition for inhalation comprising R (+) budesonide and one or more bronchodilators, and, optionally, one or more pharmaceutically acceptable excipients is described. | 2021-10-07 |
20210308151 | ACTIVATING ENDOGENOUS ANTIMICROBIALS TO TREAT SARS-COV-2 INFECTION - Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided. | 2021-10-07 |
20210308152 | ANACARDIC ACID FOR NEURAL REPAIR - Methods for stimulating neural repair and remyelination and for treating a myelin related disorder in a subject are described. The methods include administering to a subject in need of treatment an effective amount of anacardic acid having the formula (I) of claim | 2021-10-07 |
20210308153 | HALOGENATED SALICYLANILIDES FOR TREATING CLOSTRIDIUM INFECTIONS - The present invention relates to halogenated salicylanilides, or pharmaceutically acceptable salts or esters thereof, for use in the treatment of an infection in a subject caused by | 2021-10-07 |
20210308154 | Methods and Compositions for Treating Meibomian Gland Dysfunction - The invention provides methods, compositions, and kits containing a minocycline topical suspension, for treating meibomian gland dysfunction and related disorders. | 2021-10-07 |
20210308155 | PHARMACEUTICAL COMPOSITIONS, METHOD OF MAKING AND METHOD OF USING THEREOF - Pharmaceutical compositions suitable for long-term storage at room temperature are described. The pharmaceutical composition comprises the compound of formula (I) and can be used for the treatment of steatohepatitis. Also described are methods for preparing the pharmaceutical composition and methods of treatment using the pharmaceutical compositions. | 2021-10-07 |
20210308156 | COMPOSITION, COMPRISING THIAMINE DERIVATIVE, FOR PREVENTION OR TREATMENT OF HYPERCORTISOLEMIA - The present invention relates to a composition for prevention or treatment of hypercortisolemia, the composition comprising allithiamine, fursultiamine, and benfotiamine, which are all derivatives of thiamine, or a mixed composition thereof. The composition for prevention or treatment of hypercortisolemia of the present invention can effectively treat or alleviate symptoms or disorders resulting from excessive secretion of cortisol, without surgical operations, and does not exhibit side effects caused by conventional medications. | 2021-10-07 |
20210308157 | STIMULATION OF AN IMMUNE RESPONSE BY ENANTIOMERS OF CATIONIC LIPIDS - A composition and method for activating immune cells ex-vivo, or inducing an immune response in a subject including a composition comprising at least one chiral cationic lipid. The chiral cationic lipid in one embodiment comprises a nonsteroidal cationic lipid having a structure represented by formula (I); wherein in R | 2021-10-07 |
20210308158 | SYNTHETIC COMPOSITION AND METHOD FOR TREATING IRRITABLE BOWEL SYNDROME - The application relates to a method for treating a patient with irritable bowel syndrome (IBS), the method comprising administering to the patient one or more neutral human milk oligosaccharides (HMOs) selected from 2′-fucosyllactose (2′-FL), 3-fucosyllactose (3-FL), difucosyllactose (DFL), lacto-N-fucopentaose I, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), and combinations thereof | 2021-10-07 |
20210308159 | COMPOSITION COMPRISING HMSs/HMOs AND USE THEREOF - The application relates to a method for the prophylaxis or treatment of non-infectious diarrhea in a human, the method comprising administering to the human an effective amount of one or more human milk oligosaccharides. | 2021-10-07 |
20210308160 | N-PALMITOYL-D-GLUCOSAMINE IN A MICRONIZED FORM - The present invention relates to an N-palmitoyl-D-glucosamine-based composition in a micronized form, optionally in combination with Curcumin. | 2021-10-07 |
20210308161 | ALTERING CANCER CELLULAR FUNCTIONS THROUGH PROTON MOPPING - Proton mopping is a new anti-cancer therapeutic approach that disrupts cancer's immunologic balance. It results in the alteration of the pHi/pHe ratio (intracellular-extracellular) of the cancer cell, leading cancer to either normalcy or apoptosis. This technology deploys a chemical compound that has two parts, a glucose part to guide the molecule to the cancer site and a proton neutralizer to mop up the protons. Proof of the validity of this therapeutic approach came after using an existing chemical compound 2-[2(2-Aminoethoxy)ethoxy]ethyl a-D-mannopyranoside, C | 2021-10-07 |
20210308162 | NOVEL TLR4 INHIBITORS FOR THE TREATMENT OF HUMAN INFECTIOUS AND INFLAMMATORY DISORDERS - The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role. | 2021-10-07 |
20210308163 | COMPOSITIONS COMPRISING RESVERATROLOSIDES AND CURCUMINS - The invention refers to new methods for treating spontaneous tumors in humans of the Central Nervous System, more particularly of 3rd and 4th grade tumors, even more particularly gliomas, and is related to the administration of compositions comprising therapeutically effective amounts of resveratrolosides and curcumins, in particular natural extracts comprising said two components. The invention also relates to the realization of pharmaceutical and nutraceutleal compositions comprising resveratrolosides and curcumins More specifically, the invention relates to compositions formulated for the release of active components for sublingual administration. | 2021-10-07 |
20210308164 | ANTIMICROBIAL FORMULATIONS COMPRISING VANCOMYCIN OR TOBRAMYCIN - The present invention relates to antimicrobial formulations comprising Vitamin D as carrier loaded with an antibiotic. More specifically, the present invention relates to antimicrobial compositions comprising vitamin D as carrier loaded with an antibiotic for controlling infections and managing potentially infected wounds or infected wounds or treating infected implants used in orthopaedic surgery and various other conditions leading to healing of the wounds and avoidance of development of antibacterial resistance and avoiding complications related to the use of prolonged antibiotics by systemic route. | 2021-10-07 |
20210308165 | COMPOSITION COMPRISING PUNICALAGIN FOR INHIBITING PAR2 ACTIVITY - The present invention relates to a composition for inhibiting PAR2 activity including punicalagin, and more specifically, the present invention provides a composition for inhibiting PAR2 activity including punicalagin, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition, health functional food composition, or cosmetic composition for preventing or treating an inflammatory disease or pruritis. | 2021-10-07 |
20210308166 | ANTIOXIDANT COMPOSITION COMPRISING NOVEL GINSENOSIDE - The present specification relates to a composition comprising (20S,24R)-6-O-β-D-glucopyranosyl(1->2)-β-D-glucopyranoside-dammar-3-one-20,24-epoxy-6a,12b,25-triol, which is a novel ginsenoside, and pharmaceutically acceptable salts thereof, a hydrate thereof or a solvate thereof as an active ingredient. The composition exhibits an excellent antioxidant effect. | 2021-10-07 |
20210308167 | METHODS OF PREVENTING AND TREATING COVID-19 INFECTION - A method of treating an individual infected with COVID-19, the method comprising the steps of providing an individual infected with COVID-19; and administering five antimicrobials to the individual, wherein the antimicrobials comprise: hydroxychloroquine; azithromycin; vitamin C; vitamin D; and zinc. | 2021-10-07 |
20210308168 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO - Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can include tongaviridae, bunyaviridae, arenaviridae, coronaviridae, flaviviridae, picornaviridae, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infections. | 2021-10-07 |
20210308169 | METHODS AND COMPOSITIONS FOR TREATMENT OF RETINAL DEGENERATIVE DISEASES - The present invention relates to an isolated nucleic acid molecule comprising i) a nucleotide sequence coding for a hyperpolarizing light-gated ion channel or pump gene from an archeon or for a light-active fragment of said gene, or the nucleotide sequence and ii) a nucleotide sequence coding for a neurotrophic factor for use in the treatment of a retinal degenerative disease. | 2021-10-07 |
20210308170 | COMPOSITION FOR SUPPRESSION OF AGING, PREVENTION, AMELIORATION, OR TREATMENT OF AN AGE-RELATED DISEASE OR SYMPTOM, OR EXTENSION OF LIFESPAN - It was found that Rubicon is involved in aging through suppression of autophagic activity, and it is possible to achieve suppression of aging, prevention, amelioration, or treatment of an age-related disease or symptom, or extension of lifespan, by targeting Rubicon. | 2021-10-07 |
20210308171 | METHODS FOR COMBINATORIAL SCREENING AND USE OF THERAPEUTIC TARGETS THEREOF | 2021-10-07 |
20210308172 | ADMINISTRATION OF SYNERGISTIC AMOUNTS OF MODIFIED CITRUS PECTIN AND HONOKIOL TO TREAT INFLAMMATION AND ANTI-OXIDANT NEEDS - A method of inhibiting or reducing inflammation in a mammal comprises administering MCP or similar Gal-3 binding moiety with honokiol in a range of about 8-10:1, by weight, MCP to honokiol. By pursuing complimentary pathways, a synergistic combination is achieved, where the reduction or degree of inflammation inhibition is greater than would be expected by the added administration of these two agents. The inflammation may be manifested as gingivitis, which may be addressed by a preparation comprising honokiol and MCP, or an MCP equivalent, in the indicated range by weight, where they are in the form of an oral rinse, lozenge, sucking candy, toothpaste or tablet. | 2021-10-07 |
20210308173 | PHARMACEUTICAL COMPOSITION COMPRISING CYCLODEXTRIN COMPLEXES OF ANETHOLE TRITHIONE OR DERIVATIVES THEREOF - A composition including anethole trithione or a derivative thereof of formula (I), sulfobutyl ether-beta-cyclodextrin and optionally a co-solvent, wherein the ratio of the sulfobutyl ether-beta-cyclodextrin to the compound of formula (I) ranges from 10 to 400, preferably from 57 to 200. Also, the use of the composition as a drug, namely for the treatment and/or the prevention of free oxygen radical-related diseases. Further, a kit-of-parts and/or a medical device including the composition. Lastly, a method for solubilizing a compound of formula (I) in an aqueous medium. | 2021-10-07 |
20210308174 | TREATMENT OF IRRITABLE BOWEL SYNDROME WITH MOLYBDENUM - Described are methods for treating or preventing IBS in subjects by administering molybdenum or a salt thereof to subjects having or prone of getting IBS. The molybdenum has been shown to treat or prevent IBS in subjects administered this agent when compared to reference subjects not administered molybdenum. | 2021-10-07 |
20210308175 | Systems And Methods To Improve Organ Or Tissue Function And Organ Or Tissue Transplant Longevity - The present invention provides for systems and methods for inhaled CO therapy to prevent, attenuate, or delay processes that accelerate the loss of organ or tissue function, thereby increasing the lifespan of transplanted organs or tissues, or slowing the decline of native organs or tissues, or delaying the need for replacement of diseased native organs with organ transplants. Such biological processes that are prevented, attenuated, or delayed include chronic persistent inflammation, fibrosis, scarring, as well as immunologic or autoimmune attack. | 2021-10-07 |
20210308176 | HYPERTONIC PHARMACEUTICAL COMPOSITIONS CONTAINING AN ANTI-PLATINUM CHEMOPROTECTANT AGENT - Hypertonic pharmaceutical compositions are disclosed. The hypertonic pharmaceutical compositions contain an anti-platinum chemoprotectant agent and a gelling agent. Also disclosed are methods of medical use of the hypertonic pharmaceutical compositions. | 2021-10-07 |
20210308177 | Method and Composition for Enhancing the Quality and Benefits of Sleep - Compounds, compositions and methods of making and using for enhancing the quality and benefit of sleep and/or wakefulness in a subject in need thereof. | 2021-10-07 |
20210308178 | AMORPHOUS CALCIUM CARBONATE STABILIZED WITH POLYPHOSPHATES OR BISPHOSPHONATES - The present invention provides solid compositions of amorphous calcium carbonate (ACC) and a polyphosphate, bisphosphonate or pharmaceutical salts thereof as a stabilizer. Said stabilizers stabilizes the ACC and prevent crystallization to crystalline calcium carbonate (CCC) for a long period of time, even in an aqueous suspension. The invention further provides pharmaceutical composition comprising the solid ACC compositions as well their use in treating of certain diseases and conditions. | 2021-10-07 |
20210308179 | ISOTONIC CRYSTALLOID AQUEOUS SOLUTION - The invention relates to an isotonic crystalloid aqueous solution of the type containing Na | 2021-10-07 |
20210308180 | COMPOSITION FOR PREVENTING OR TREATING COVID-19, INCLUDING GOLD NANOPARTICLE AS ACTIVE INGREDIENT - The present invention relates to a pharmaceutical composition for treating or preventing coronavirus infection (COVID-19), containing a gold nanoparticle. In the present invention, the gold nanoparticles hinder the morphological change of a coronavirus protein to block the entry of the coronavirus protein into cells, resulting in prevention or treatment of the coronavirus infection (COVID-19). | 2021-10-07 |
20210308181 | ENTERIC AEROBIZATION THERAPY - Agents, kits, and methods that utilize oxygenation to prevent and/or treat infections caused by anaerobic microorganisms are provided. The agents, kits, and methods according to several embodiments utilize oxygenation in the intestinal lumen to prevent and/or treat infections caused by anaerobic bacteria. The agents, kits, and methods can be utilized to prevent and/or treat anaerobic bacterial infections of the intestinal lumen by enteric aerobization therapy. | 2021-10-07 |
20210308182 | REGULATORY T CELL EPITOPES - The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprises a polypeptide comprising at least a portion of SEQ NOS: 1-124 (and/or fragments and variants thereof), and optionally 1 to 12 additional amino acids distributed in any ratio on the N-terminus and/or C-terminus of the polypeptide of SEQ ID NOS: 1-124, as well as methods of producing and using the same. | 2021-10-07 |
20210308183 | CHIMERIC ANTIGEN RECEPTOR T CELLS DERIVED FROM IMMUNOENGINEERED PLURIPOTENT STEM CELLS - The invention provides universally acceptable “off-the-shelf” hypoimmune pluripotent (HIP) cells and hypoimmune chimeric antigen receptor T (CAR-T) cells derived from the HIP cells. The engineered therapeutic cells can be administered to subjects as an adoptive cell-based immunotherapy to treat cancer. | 2021-10-07 |
20210308184 | TAG72 TARGETED CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS FOR TREATMENT OF TAG72-POSITIVE TUMORS - Chimeric antigen receptors targeted to TAG72 and the use thereof to treat ovarian cancer and other cancers are described | 2021-10-07 |
20210308185 | METHODS OF TREATING ACQUIRED HEMOPHILIA WITH ANTI-FIBRINOLYTIC LOADED PLATELETS - Provided herein are methods and compositions for treating acquired hemophilia with platelets and/or platelet derivatives. In some cases, the platelets and or platelet derivatives are loaded with an anti-fibrinolytic. | 2021-10-07 |
20210308186 | Treatment of Acute Respiratory Distress Syndrome by T Regulatory Cells - Described are means, methods and compositions of matter for treatment of acute respiratory distress syndrome (ARDS) by enhancement of T regulatory (Treg) number and/or efficacy. In one embodiment of the invention, exogenous Tregs are administered. In another embodiment, enhanced endogenous Tregs are provided using methods including administration of low dose interleukin-2, administration of other cytokines, and administration of cells which stimulate Treg generation such as mesenchymal stem cells. | 2021-10-07 |
20210308187 | MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA - This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. | 2021-10-07 |
20210308188 | CELL CLUSTER INCLUDING OLFACTORY NEURON OR PRECURSOR CELL THEREOF, AND METHOD FOR PRODUCING SAME - A method for producing a cell cluster including an olfactory receptor neuron or a precursor cell thereof, comprising the following steps (1) to (3): step (1) of suspension-culturing a pluripotent stem cell in the presence of a Wnt signaling pathway inhibitory substance to form a cell aggregate; step (2) of suspension-culturing the cell aggregate obtained in the step (1) in the presence of a BMP signaling pathway-activating substance; and step (3) of suspension-culturing the cell aggregate obtained in the step (2) to obtain the cell cluster, wherein step (3) comprises at least one step selected from the group consisting of: step (3a) of suspension-culturing in the presence of an FGF signaling pathway-activating substance; step (3b) of suspension-culturing in the presence of a BMP signaling pathway inhibitory substance; and step (3c) of culturing in the presence of an FGF signaling pathway-activating substance and a BMP signaling pathway inhibitory substance. | 2021-10-07 |
20210308189 | METHODS, COMPOSITIONS, AND KITS FOR IMPROVING PANCREATIC BETA CELL VIABILITY AND TREATING DISEASES OR CONDITIONS RELATED TO BETA CELL DESTRUCTION - The present disclosure provides novel methods for increasing β-cell viability in islets by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to the islets. The disclosure also provides novel methods for treating a disease or condition in a subject, such as type 1 diabetes mellitus, by delivering RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, to islets and transplanting the islets into the subject to treat the disease or condition. Kits and compositions including RLIP76 polypeptides or GSTA4 polypeptides, or a combination thereof; or RLIP76 polynucleotides or GSTA4 polynucleotides, or a combination thereof, are also provided to increase β-cell viability. | 2021-10-07 |
20210308190 | HUMAN UMBILICAL CORD BLOOD MESENCHYMAL STEM CELL TRANSFUSION IMMUNOTHERAPY FOR TREATMENT OF CYTOKINE STORM ASSOCIATED WITH CORONAVIRUS INFECTION - A method for administering human umbilical cord blood mesenchymal stem cell transfusion immunotherapy to a patient for treatment of coronavirus infection. The method includes harvesting umbilical cord mesenchymal stem cells, culturing the stem cells, collecting and purifying the cultured stem cells, placing the purified stem cells into a transfusion bag, and intravenously transfusing the stem cells from the transfusion bag into the patient having the infection. | 2021-10-07 |
20210308191 | Drug Used for Treating Tissue Necrosis or for Improving Cardiac Function - A drug used for treating ischemia and hypoxia-induced tissue necrosis or for improving cardiac function; the drug contains amniotic fluid from a non-human animal and/or an extract thereof, and an optional pharmaceutically acceptable carrier, wherein the amniotic fluid comes from chicken eggs having an embryonic age of 5-12 days, eggs from other birds corresponding to the described developmental period, embryos from rodents having a gestational age of 8-20 days, or embryos from other non-human mammals corresponding to the described developmental period. The drug may promote the growth of human umbilical vein endothelial cells, AC16 cells and chicken embryo fibroblasts, improve cardiac function after myocardial infarction, and promote cardiac cell regeneration after a myocardial infarction. | 2021-10-07 |
20210308193 | KRILL OIL COMPOSITION ENRICHED IN LPC-DHA AND LPC-EPA - The present invention provides compositions comprising phosphatidylcholine derived compounds carrying an omega-3 fatty acid for use in prophylaxis or therapy, particularly when administered systemically. This invention further relates to a modified krill oil composition enriched in LPC-DHA and LPC-EPA, methods of making and methods of using to treat neurological and ocular disorders. | 2021-10-07 |
20210308194 | Coral Composite Extract, Composition Including The Same And Method Of Producing The Same - The present invention relates to a coral composite extract, a composition including the same and a method of producing the same. The coral composite extract includes at least two briarane-type diterpenoid compounds from corals of | 2021-10-07 |
20210308195 | PROGRAMMABLE BACTERIA FOR THE TREATMENT OF CANCER - Disclosed herein are programmable bacteria for tumor-targeted immunotherapeutic delivery. In certain embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon which are capable of being further engineered to cyclically produce anti-cancer therapeutic agents including but not limited to nanobodies against immune checkpoint inhibitors and over-expressed markers in cancers, toxins, tumor antigens, cytokines, and chemokines. In some embodiments, the programmable bacteria comprise at least one synchronized lysis circuit contained in a single operon and at least one plasmid producing a therapeutic agent, i.e., at least one plasmid comprising a nucleic acid sequence which encodes a therapeutic agent. The disclosure also provides methods of curing and treating cancer using the programmable bacteria. | 2021-10-07 |
20210308196 | COMPOSITIONS AND METHODS TO PROMOTE HOST DEFENSE AND STIMULATE, EXPAND, AND/OR RESET T CELL REPERTOIRES - Compositions comprising vitamin A, vitamin D, threonine, mammalian milk oligosaccharides, and | 2021-10-07 |
20210308197 | COMPOSITION COMPRISING LACTIC ACID BACTERIA FOR USE IN THE PREVENTIVE AND/OR CURATIVE TREATMENT OF RECURRENT CYSTITIS - A composition comprising lactic bacteria for use in the preventive and/or curative treatment of bacterial infections, which cause urinary tract and/or bladder inflammations is described. The composition is in particular for the treatment of recurrent cystitis. | 2021-10-07 |
20210308198 | COMPOSITIONS AND METHODS FOR INHIBITING THE PROLIFERATION OF PATHOGENIC ESCHERICHIA COLI - A composition for preventing or treating an infection or disease caused by a pathogenic | 2021-10-07 |
20210308199 | ACTIVE SUBSTANCE OF MORCHELLA, ITS USE AND A COMPOSITION THEREOF FOR IMPROVING THE REPRODUCTIVE FUNCTION - The present invention provides an active substance of | 2021-10-07 |
20210308200 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY RESPONSE - Described herein are mushroom compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect the composition comprises an aqueous or solid fraction of a mycelium, a fermented substrate thereof, or a combination thereof optionally combined with one or more buffering agents, ethanol, and water. | 2021-10-07 |
20210308201 | COMPOSITIONS AND METHODS FOR MODULATING INFLAMMATORY RESPONSE - Described herein are mushroom compositions and methods for treating, prophylaxis of, or ameliorating symptoms of one or more adverse reactions triggered by an infectious disease or condition that increases an anti-inflammatory response in a subject with such compositions. In one aspect the composition comprises an aqueous or solid fraction of a mushroom mycelium and/or fruit body mixture, optionally combined with one or more buffering agents, ethanol, and water. | 2021-10-07 |
20210308202 | BRASSICA EVENTS LBFLFK AND LBFDAU AND METHODS FOR DETECTION THEREOF - The present invention provides transgenic | 2021-10-07 |
20210308203 | Compositions for preventing or treating diseases or disorders associated with by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage and uses thereof - Provided herein are compositions for treating a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage in a subject, pharmaceutical compositions comprising the compositions and pharmaceutically acceptable excipients, and nutraceutical compositions comprising the compositions and nutraceutically acceptable excipients. Provided also herein are methods of treating a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage in a subject in need thereof, methods of reducing, alleviating, or delaying a sign or a symptom of a disorder characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage in a subject in need thereof, and methods of regulating inflammation, antioxidant enzymes, and apoptosis in a subject having a disorder or a disease associated with or characterized by neuro-inflammation, neuro-apoptosis, or neuro-oxidative damage. | 2021-10-07 |
20210308204 | FORMULATIONS CONTAINING LIPOPHILIC EXTRACTS OF SPICY EDIBLE PLANTS USEFUL IN CONTROLLING PAIN AND INFLAMMATION - The present invention concerns with new compositions containing lipophilic extracts of | 2021-10-07 |
20210308205 | METHOD FOR REDUCING FAT ACCUMULATION BY USING TETRAMETHYLISOSCUTELLAREIN - The present disclosure provides an extract of early-harvested | 2021-10-07 |
20210308206 | ACTIVIN TYPE 2 RECEPTOR BINDING PROTEINS AND USES THEREOF - This disclosure provides ActRII-binding proteins such as anti-ActRIIA and anti-ActRIIB antibodies, and compositions and methods for making the ActRII-binding proteins. In certain aspects the ActRII-binding proteins inhibit, or antagonize ActRII activity. In addition, the disclosure provides compositions and methods for diagnosing and treating diseases and conditions associated muscle wasting; a fibrotic condition; an inflammatory, cardiovascular, pulmonary, musculoskeletal, neurologic, ocular, skeletal, autoimmune, or metabolic disease or condition; wound healing; and cancer, and other ActRII-mediated diseases and conditions. | 2021-10-07 |
20210308207 | COMPOUNDS COMPRISING A LINKER FOR INCREASING TRANSCYCLOOCTENE STABILITY - Disclosed are compounds having a linker for increasing trans-cyclooctene stability. The linker of the invention is a three-arm linker. In some embodiments, one arm of the linker is attached to a trans-cyclooctene moiety, another arm is attached to a compound selected from the group consisting of antibodies, proteins, peptides, and peptoids, and the third arm extends into the solution. | 2021-10-07 |
20210308208 | ANTI-TISSUE FACTOR ANTIBODY-DRUG CONJUGATES AND THEIR USE IN THE TREATMENT OF CANCER - The invention provides methods and compositions for treating cancer, such as ovarian cancer, peritoneal cancer, and fallopian tube cancer, in a subject, such as by the administration of antibody-drug conjugates that bind to tissue factor (TF). The invention also provides articles of manufacture and compositions comprising said antibody drug-conjugates that bind to TF for use in treating cancer (e.g., ovarian cancer, peritoneal cancer, and fallopian tube cancer). | 2021-10-07 |
20210308209 | COMBINATION THERAPY FOR ISCHEMIA - The invention provides a combination treatment for ischemia conditions in or otherwise affecting the CNS, such as stroke. The treatment involves administration of a PSD-95 inhibitor and performing reperfusion therapy (e.g., by administration of tPA). Administering a PSD-95 inhibitor in combination with reperfusion therapy increases the efficacy of the reperfusion therapy and/or slows the decline in efficacy of reperfusion therapy with time after onset of ischemia thus extending the window in which reperfusion therapy can be administered. | 2021-10-07 |
20210308210 | MACROCYCLIC PEPTIDES TO DECREASE C-MYC PROTEIN LEVELS AND REDUCE CANCER CELL GROWTH - The present technology provides methods end medicaments useful for treating prostate cancer and breast cancer. Such methods include administering at least one of cyclo[Phe-D-Pro-Phe-Trp] and cyclo[Phe-D-Pro-Phe-D-Trp] to a subject suffering from prostate cancer or breast cancer. | 2021-10-07 |
20210308211 | METHOD OF TREATING VIRAL INFECTIONS - The present disclosure relates to methods of treating, preventing, or ameliorating at least one symptom of a viral infection or virus-induced immunopathology in a subject in need thereof, as well as methods of modulating the immune response in a subject having a viral infection. The methods include: administering an effective amount of a pharmaceutical composition that includes an effective amount of a peptide having the amino acid sequence as set forth in SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, a salt form thereof, or combination thereof; and at least one pharmaceutically acceptable carrier or excipient. | 2021-10-07 |
20210308212 | Reagents and methods for treating bacterial infection - Disclosed herein are α-sheet peptides and their use for treating a bacterial infection and/or limiting bacterial biofilm formation. | 2021-10-07 |
20210308213 | METHOD FOR DIAGNOSING AND TREATING CANCER USING NA VE STATE STEM CELL SPECIFIC GENES - The present application discloses a method for converting a cell to naïve state stem cells comprising contacting the cell to be converted with an NME protein. | 2021-10-07 |
20210308214 | COMPOSITIONS OF STING VARIANTS, COMBINATIONS THEREOF, AND METHODS FOR INDUCING AND ENHANCING AN IMMUNE RESPONSE AGAINST INFECTIONS, DISEASES, AND DISORDERS - The present invention relates to compositions and methods for modulating immune responses using at least one STING variant. Also provided are compositions comprising at least one STING variant, in combination with at least one cyclic di-nucleotide synthetase enzyme. Such compositions may be combined with a number of other therapeutic agents which target modulating immune responses, as well as, treatments that include immune events. | 2021-10-07 |
20210308215 | METHODS AND COMPOSITIONS FOR TREATING DIABETES, AND METHODS FOR ENRICHING MRNA CODING FOR SECRETED PROTEINS - A previously uncharacterized gene and gene product are disclosed herein that increase blood glucose clearance independent of insulin. Also described is a methodology for enriching for mRNAs transcribing excreted and membrane bound proteins as well as a non-human animal expressing a labeled SEC61b protein. | 2021-10-07 |
20210308216 | USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS - The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization. | 2021-10-07 |
20210308217 | USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS - The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization. | 2021-10-07 |
20210308218 | GALECTIN-1 IMMUNOMODULATION AND MYOGENIC IMPROVEMENTS IN MUSCLE DISEASES AND AUTOIMMUNE DISORDERS - Limb-girdle muscular dystrophy type 2B (LGMD2B) is caused by mutations in the dysferlin gene, resulting in non-functional dysferlin, a key protein found in muscle membrane. Treatment options available for patients are chiefly palliative in nature and focus on maintaining ambulation. A method of treating LGMD2B is disclosed herein. The method includes administering to a patient a suitable amount of a galectin protein or fragment thereof. Treatment with a recombinant galectin promoted myogenic maturation as indicated through improvements in size, myotube alignment, myoblast migration, and membrane repair capacity in dysferlin-deficient myotubes, explant myofibers and mice. | 2021-10-07 |
20210308219 | Transgenic Corn With Antifungal Peptide AGM182 (DN:0113.18) - is an opportunistic, saprophytic fungus that infects maize and other fatty acid-rich food and feed crops and produces toxic and carcinogenic secondary metabolites known as aflatoxins. In vitro studies showed a five-fold increase in antifungal activity of AGM182 (vs. tachyplesin1) against | 2021-10-07 |
20210308220 | Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody - A method of treating Crohn's disease in a patient administers an IL-23 specific antibody, e.g., guselkumab, at an initial intravenous dose and subsequence subcutaneous doses. | 2021-10-07 |
20210308221 | TREATMENT WITH GDF11 PREVENTS WEIGHT GAIN, IMPROVES GLUCOSE TOLERANCE AND REDUCES HEPATOSTEATOSIS - Disclosed herein are a means to prevent and/or ameliorate age, disease and obesity associated metabolic diseases, such as diabetes and impaired glucose tolerance. Also disclosed are compositions and methods that relate to the findings that GDF11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis in aged mice administered a high fat diet. In particular, the methods and compositions described herein relate to increasing the level of GDF11 in a subject, thereby treating or preventing the development of obesity in the subject, reducing the metabolic consequences of obesity and improving the subject's metabolic health. | 2021-10-07 |
20210308222 | IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES - This disclosure provides for a method for treating a condition by administering to a subject in need thereof a therapeutically-effective amount of a compound that comprises an IL-2 receptor-binding moiety. The methods described in the present disclosure provide enhanced pharmacokinetic profiles. The disclosure also provides methods for treating autoimmune disease comprising administering a therapeutically-effective amount of a fusion protein comprising an IL-2 variant protein. | 2021-10-07 |
20210308223 | PEPTIDE YY PHARMACEUTICAL FORMULATIONS, COMPOSITIONS, AND METHODS - Pharmaceutical compositions comprising PYY (e.g., PYY(3-36) and analogs and variants thereof), satiety peptides, satiety hormones, metabolic hormones, and methods of treating metabolic diseases with such compositions are provided. Aspects include methods of increasing a feeling of fullness in patients treated with pharmaceutical compositions comprising PYY, PYY(3-36), satiety peptides, satiety hormones, metabolic hormones, and analogs, receptor antagonists and variants thereof. | 2021-10-07 |
20210308224 | TREATMENT FOR SARS-COV-2 AND OTHER CORONAVIRUSES - A method of treating a corona virus infection in a human includes administering to the human an effective amount of at least one a natriuretic peptide (NP) and a neprilysin inhibitor (NI). A pharmaceutical composition for the treatment of corona virus in a human includes one of a recombinant natriuretic peptide (rNP) and a chimeric natriuretic peptide D (CD-NP) and a pharmaceutically acceptable carrier. | 2021-10-07 |
20210308225 | Long-Acting Formulations of Insulin - The application relates to an aqueous pharmaceutical formulation comprising 200-1000 U/mL [equimolar to 200-1000 IU human insulin] of insulin glargine. | 2021-10-07 |
20210308226 | CONTROLLED RELEASE PEPTIDE FORMULATIONS - The present invention relates to compositions forming a low viscosity mixture of: | 2021-10-07 |
20210308227 | LYOPHILIZED RECOMBINANT VWF FORMULATIONS - The present invention provides long-term stable pharmaceutical formulations of lyophilized recombinant von-Willebrand Factor (rVWF) and methods for making and administering said formulations. | 2021-10-07 |
20210308228 | METHOD FOR REDUCING THE OCCURRENCE OF THROMBOSIS OR THROMBOEMBOLISM - The present disclosure refers to a method and compositions for reducing the occurrence of thrombosis or thromboembolism in a patient identified as being at risk thereof, the method comprising administering to the patient a therapeutically effective amount of one or more anticoagulant selected from the group consisting of unfractionated heparin, a low molecular weight heparin, a heparinoid, fondaparinux, idraparinux, and combinations thereof, and antithrombin III (ATIII). | 2021-10-07 |
20210308229 | METHOD FOR IMPROVING THE STABILITY OF PURIFIED FACTOR VIII AFTER RECONSTITUTION - The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection. | 2021-10-07 |
20210308230 | METHODS FOR TREATING DISEASES ASSOCIATED WITH RESPIRATORY VIRUSES - The present disclosure provides a method of treating a disease associated with a respiratory virus. The method comprises administering an effective amount of a pharmaceutical composition prepared by removing albumin from a solution of a human serum albumin composition and/or comprising a diketopiperazine with amino acid side chains of aspartic acid and alanine (DA-DKP), such as a low molecular weight fraction of human serum albumin. The present disclosure also provides a pharmaceutical product as well as a kit comprising DA-DKP. | 2021-10-07 |
20210308231 | COLLAGEN HYDROLYSATE FOR USE WITH SKIN DISORDERS AND INTESTINAL DISORDERS - The present invention relates to collagen hydrolysate for use as an active substance in the treatment of inflammatory skin disorders and intestinal disorders and/or skin disorders and intestinal disorders accompanied by inflammation. | 2021-10-07 |
20210308232 | TREATEMENT OF PATHOGEN INFECTIONS FORMULATIONS AND METHODS FOR USE - An oral product comprising nano-sized, heat tolerable, shelf stable peptides and enzymes. Once the peptides and enzymes are inside the body of a user, they dimerize the nucleic acids of viruses, bacteria and fungi. Thus, the peptides and enzymes are capable of inactivating the genome of pathogens, including without limitation, SARS-CoV-2 and Influenza A/CA/04/2009 (H1N1) virus. | 2021-10-07 |